December 22, 2017
Authors: Widschwendter M, Evans I, Jones A, et al.
Journal: Genome Med. 2017 Dec 22;9(1):115. doi: 10.1186/s13073-017-0499-9.
Intro: Genedata scientists and colleagues in the EpiFemCare consortium detected serum DNAme patterns which offer a new tool for early diagnosis and management of disseminated breast cancers.
Abstract: Monitoring treatment and early detection of fatal breast cancer (BC) remains a major unmet need. Aberrant circulating DNA methylation (DNAme) patterns are likely to provide a highly specific cancer signal. We hypothesized that cell-free DNAme markers could indicate disseminated breast cancer, even in the presence of substantial quantities of background DNA ... Detection of EFC#93 serum DNAme patterns offers a new tool for early diagnosis and management of disseminated breast cancers. Clinical trials are required to assess whether EFC#93-positive women in the absence of radiological detectable breast cancers will benefit from anti-hormonal treatment before the breast lesions become clinically apparent.
Keywords: Cell-free DNA, DNA methylation, Serum DNA, Breast cancer, Early diagnosis, Personalized treatment